Clinical Trial Detail

NCT ID NCT02283177
Title A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Arog Pharmaceuticals LLC
Indications

acute myeloid leukemia

Therapies

Crenolanib + Cytarabine + Daunorubicin

Age Groups: senior adult

Additional content available in CKB BOOST